ATR inhibitors Archives

Artios, Novartis Form Cancer Partnership

ATR inhibitors, Business, Cancer, Collaborations, DNA Damage Response (DDR), Francis Crick Institute, Novartis, PARP Inhibitors, Partnerships

Artios Pharma entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DNA damage response (DDR) targets and enhancing Novartis’ radioligand therapies.

April 7, 2021/by Andrew Humphreys

Merck KGaA’s ATR Inhibitor Shows Promise in Cancer and Covid-19

ATR inhibitors, ATR protein, Biopharma, Cancer, Coronavirus Disease 2019 (COVID-19), DNA, DNA Repair, Kinase Inhibitors, Los Angeles (UCLA), R&D, SARS-CoV-1, Small Molecules

According to a research collaboration among UCLA investigators and Merck KGaA, berzosertib has shown promise for Covid-19 and is also being touted for the drug’s unusually broad effect in treating a range of cancers.

March 30, 2021/by Andrew Humphreys